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Several recent studies have established an association between abnormalities of complement factor H (FH) and the
development of hemolytic uremic syndrome (HUS). To identify the relative importance of mutations in FH as a
cause of HUS, we have undertaken mutation screening of the FH gene in 19 familial and 31 sporadic patients with
FH. Mutations were found in two familial and three sporadic patients, and these clustered in exons 18–20, a
domain important for host recognition. Moreover, this study demonstrates that familial HUS is likely to be a
heterogeneous condition.
Hemolytic uremic syndrome (HUS) (MIM 134370) is
characterized by the triad of microangiopathic hemolytic
anemia, thrombocytopenia, and acute renal failure. It
can be classified as diarrheal (d HUS) or nondiarrheal
(d HUS), which in turn are classified as either sporadic
or familial. Since Thompson and Winterborn’s obser-
vation (1981) of two brothers with HUS and low levels
of factor H (FH), there have been a number of reports
of low FH levels in patients with HUS (Roodhooft et al.
1990; Pichette et al. 1994; Ohali et al. 1998; Rougier
et al. 1998; Warwicker et al. 1998; Noris et al. 1999).
The alternative complement pathway distinguishes
host from foreign tissue, and FH is both a key recog-
nition protein in the system and a down-regulator of
alternative pathway activity (Pangburn et al. 2000). C3b
is continually deposited on all cell surfaces in contact
with the blood. If it binds factor B, the alternative path-
way is activated, leading to formation of the membrane
attack complex and cell lysis. FH binds to host cell sur-
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faces and competes with factor B to bind C3b. FH is
also a cofactor for factor I–mediated breakdown of the
C3 convertase C3bBb and has independent decay-
accelerating properties (Zipfel et al. 1999).
FH is located in the “regulators of complement acti-
vation” cluster on chromosome 1. This gene cluster in-
cludes decay-accelerating factor, complement receptors
type 1 and 2, membrane cofactor protein, C4-binding
protein, clotting factor XIIIb, FH, and the FH-related
protein genes (FHR1, FHR2, FHR3, and FHR4) (Zipfel
and Skerka 1994; Pardo-Manuel de Villena et al. 1996;
DiazGuillen et al. 1999; Zipfel et al. 1999). The gene
family has arisen by multiple duplication events. Each
of these genes encodes proteins, which consist of mul-
tiple (contiguous) homologous modules called “comple-
ment control protein modules” (CCPs). CCPs were pre-
viously known as short consensus repeats (SCRs). Each
CCP is ∼60 amino acids in length and has four cysteine
residues that form two disulphide bridges, Cys1–Cys3
and Cys2–Cys4 (Schmidt et al. 1999).
FH comprises 20 CCPs, each encoded by a single
exon, with the exception of the second CCP encoded by
exon 2a and 2b. There is, in addition, an alternatively
spliced product of the FH gene called “FHL1” or “re-
conectin,” which consists of the first seven CCPs. FHR1,
FHR3, and FHR4 each have five CCPs, and FHR2 has
four CCPs. There is a high level of identity between FH
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exons 18, 19, and 20 and FHR1 exons 3, 4, and 5. The
sequence identity is 100% between FH exon 18 and
FHR1 exon 3, 97% between FH exon 19 and FHR1
exon 4, and 97% between FH exon 20 and FHR1 exon
5. The respective intronic sequences also show 99%
identity (Male et al. 2000).
The molecular basis of the FH abnormality has been
reported in only two families with HUS and in a single
sporadic patient. HUS segregated as a dominant disorder
in the first family, and affected individuals had normal
FH levels. A single-base substitution leading to R1215G
was identified (Warwicker et al. 1998). In the second
family, the disorder was recessive, and FH levels were
low in affected individuals. In this family, a base pair
substitution and a 24–base pair deletion led to loss of
the last seven amino acids of CCP 20, including a cys-
teine. This resulted in aberrant folding and decreased
FH secretion (Ying et al. 1999; Buddles et al. 2000). The
sporadic patient with HUS had an exon 1–truncating
mutation on one allele and resultant half-normal FH
levels (Warwicker et al. 1998).
We have now systematically looked for FH mutations
in 19 affected individuals with one or more affected
relatives and in 31 affected individuals with no family
history of the disorder. The Newcastle and North Tyne-
side Area Health Authority Ethics Committee approved
the study. We designed intronic primers to amplify
specifically each exon of FH without amplifying the
homologous exons of FHR1. Specificity of the primers
for FH exons 18, 19, and 20 was verified by sequencing
PCR products amplified from PAC 15d12, which con-
tains the genomic sequence of FH exons 8–20, FHR1,
and FHR3. Primers and conditions are shown in table
1. Mutational screening of each exon was performed on
a panel of 50 patients (19 familial and 31 sporadic cases)
affected with HUS. Bidirectional dideoxyfingerprinting,
a technique with a high reported sensitivity and speci-
ficity, was used (Liu et al. 1996). Samples showing a
change on the nondenaturing MDE gel were further an-
alyzed by direct fluorescent sequencing of a purified PCR
product. We now describe a further five patients with
HUS and mutations in the FH gene (table 2) and one
new polymorphism. All the changes occurred in exons
18–20 (CCPs18–20). The polymorphism was in exon
18 (N1050Y) and was found in two patients with HUS,
and with an allele frequency of .04 in controls.
Two changes were observed in patient 1, a sporadic
patient. The first, in exon 18, is a heterozygous CrG
transition. This results in the substitution of the un-
charged polar amino acid glutamine (Q) by an acidic
species glutamic acid (E). The second, in exon 19, is a
heterozygous single–base pair deletion (delA3559) and
causes a frameshift that changes the terminal three
amino acids of CCP 19. This results in a lysine to as-
paragine change (K1162N), a cysteine to alanine change
(C1163A), and a leucine to tyrosine change (L1164Y).
If normal splicing of the exon 19/20 boundary occurs,
an alteration to the reading frame of exon 20 will result
leading to a premature stop codon in exon 20 after ab-
normal isoleucine (I), arginine (R), and valine (V) resi-
dues. This is shown in figure 1.
Patient 2 is a member of an affected sibling pair with
normal C3 and FH levels. A single heterozygous base
pair substitution causes the replacement of aspartic acid
(D) by the nonpolar glycine (G) in exon 19. This residue
is conserved in human FH, FHR1, and FHR3 and FH
in mouse and sand bass (Parablax nebulifer), suggesting
a functional role for this site.
Patient 3, a sporadic patient, has normal C3 and FH
levels and demonstrates the same change in exon 20
(R1215G) described by our group elsewhere (Warwicker
et al. 1998). The patient is from a different region of
the United Kingdom, with no known antecedents from
the region of the family described by Warwicker et al.
This change causes the substitution of a nonpolar amino
acid in place of a highly conserved basic amino acid.
The change is inherited from her father, who is
unaffected.
Patient 4 is a sporadic patient in whom a single het-
erozygous base pair substitution causes the replacement
of threonine (T) by arginine (R) in exon 20. FH levels
were normal but C3 was low. His unaffected mother
also shows the same change at this position. The change
results in the substitution of an uncharged polar for a
charged polar basic residue.
Patient 5 is a familial patient with an affected mother
who died from HUS. The two changes seen are identical
to the two amino acid differences between FH CCP 20
and FHR1 CCP5 (S1191L and V1197A). The changes
were shown, by sequencing of cloned products, to lie on
the same allele.
Thus, we have identified FHmutations in two patients
known to have a single affected relative (one a parent
and the other a sibling) and in three sporadic patients
with HUS, providing further evidence that FH abnor-
malities are a cause of HUS. The mutations are clustered
in exons 18–20, as shown in figure 2.
Three of the affected individuals have normal FH lev-
els, indicating a functional abnormality in the secreted
protein. This is an important observation because it
means that normal FH levels do not exclude FH as un-
derlying HUS in a particular individual. These changes
were D1119G (CCP19), T1184R (CCP20), R1215G
(CCP20), and a probable gene-conversion event chang-
ing a serine to leucine and a valine to alanine in CCP20.
These CCPs are now known to have a role both in C3b
binding and in binding to cell surfaces. FH binds to
anionic structures on cell surfaces, and thus the poly-
anion heparin has been used to identify which CCPs bind
to cell surfaces. Blackmore and colleagues (1996, 1998)
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Table 1
FH Intronic Primers and PCR Conditions
Intronic
Primer Position Primer Sequence
Annealing
Temperature
(C)
Magnesium
Concentration
(mM)
Leader Sequence F: ggagtgcagtgagaattggg 53 2.5
R: caacaatgtcaaaagccactc
1 F: ctccatagatatggggttagg 55 1.5
R: cagagccagactccatctc
2a F: ccttacattcaatctgtcttc 53 1.5
R: ccatcatagttaaactttcagg
2b F: gacactcagaatggcatcgag 55 1.5
R: gatcaggctgcattcgtttttg
3 F: cctccaatcttatcctgaggatg 55 1.5
R: gctgatattccttagaatgaacg
4 F: cctgatggaaacaacatttctg 45 2.5
R: cataaattagcactctacttttg
5 F: gccattttgtattatgctaagg 55 1.5
R: cttactttgtatatacaataagac
6 F: gagtgtttattacagtaaaatttc 53 3.0
R: gtgctctcctttcttcgatc
7 F: ttagtaactttagttcgtcttcag 55 3.0
R: ggtccattggtaaaacaaggtg
8 F: ggttttcagttacaaatgactc 53 1.5
R: gaaattatatcagcccccac
9 F: gctttttcttcttagaattgggg 53 3.0
R: caactatccttaacaattcctc
10 F: tctgatgcccctctgtatgacc 45 3.0
R: cttatttcagcaattgtaagataag
11 F: gaagaaaatctttccatttttactg 43 3.5
R: caaaatacaaaagttttgacaag
12 F: acttgtcaaaacttttgtattttg 55 1.5
R: ggaaatgttgaggcttatctg
13 F: gattaagtcataattttaccatgc 55 1.5
R: cacacatacctattacttttcc
14 F: gtgataatttatgaaacagttattg 45.6 3.5
R: ctctcttctttacacgaagcac
15 F: caaattatactcactttaaaatccg 55 3.0
R: cccctcactttgataacaagag
16 F: gtgatgtcatagtagctcctg 55 1.5
R: ctagagtccctgtttactttc
17 F: cgctattttagaatccattacatg 55 1.5
R: ggcctcccaaagtgctggg
18 F: gtaactgttatcagttgatttgc 60 1.5
R: tagccctgctatactccccc
19 F: ttcttccaggactcatttctttc 54 1.5
R: gtgagtattttgttacaaacagtg
20 F: tttattcaaatcaatatgatgtttc 53 2.5
R: agttctgaataaaggtgtgcac
NOTE.—Conditions were as follows: 94C for 4 min, then 30 cycles of 94C for 1 min,
annealing temperature for 1 min, and 72C for 1 min.
cloned a series of FH mutants in a eukaryotic expression
vector and then tested the heparin-binding capacity of
the mutant proteins. They concluded that the heparin
binding sites are CCP7 and CCP20. Further evidence
comes from the observation that a monoclonal antibody
with an epitope within CCP19 or CCP20 inhibits hep-
arin binding by FH (Prodinger et al. 1998). The basic
amino acids arginine and lysine are primarily responsible
for heparin binding, and thus the arginine to glycine
change R1215G is likely to disrupt heparin binding and
in vivo binding of FH to host cells. We have cloned each
of these mutations so that we can assess their affect on
heparin binding.
FH deficiency has also been reported in patients with
glomerulonephritis (Levy et al. 1986), systemic lupus
erythematosis (SLE) (Lopez-Larrea et al. 1987), and re-
current meningococcal meningitis (Nielsen et al. 1989).
The molecular basis has been studied in one child with
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Table 2
Mutations Detected by Bidirectional Dideoxyfingerprinting
Patient Mutation Effect CCP Family History Comments
1 C3299G Q1076E 18 Sporadic …
delA3559 Frameshift 19 Sporadic Same patient as above
2 A3429G D1119G 19 Sibling pair (D) Conserved residue
3 C3716G R1215G 20 Sporadic Previously reported in AD kindred.
(R) Conserved residue
4 C3624G T1184R 20 Sporadic …
5 C3645T
T3663C
S1191L
V1197A
20 Mother affected Probable gene-conversion event
NOTE.—Q p glutamine, Ep glutamic acid, D p aspartic acid, R parginine, G p glycine, T p
threonine, S p serine, Lp leucine, Vp valine, and Ap alanine. The system of base pair/amino acid
numbering is adapted from Ripoche et al. (1988). The amino acid number includes the 18–amino acid
leader.
Figure 1 Comparison of CCP19 and 20 wild-type amino acid sequence with the predicted sequence in patient 1 with delA3559. The
abnormal amino acids are highlighted. The vertical line indicates the boundary between CCP 19 and 20.
type II mesangiocapillary (membranoproliferative)
glomerulonephritis who had normal levels of FHL1 but
undetectable levels of FH by radioimmunoassay. He was
found to have a maternally inherited change in CCP9
(C518R) and a paternally inherited change in CCP16
(C991Y). Both of these mutations led to loss of a cysteine
residue, such that disulphide bridges essential for protein
folding could not form. Abnormal secretion of the pro-
tein was confirmed by pulse chase experiments (Ault et
al. 1997). FH deficiency inherited as an autosomal
recessive trait in the Norwegian Yorkshire pig is also
associated with mesangiocapillary glomerulonephritis
(Hogasen et al. 1995), but the molecular mechanism
responsible has not been described. There has been a
recent report of FH deficiency in a consanguineous Ital-
ian family (Sanchez-Corral et al. 2000) in which the
proband had SLE and chronic renal failure and her two
brothers had had one and three episodes of meningo-
coccal meningitis. They had a homozygous truncating
mutation in exon 3 and, hence, absence of both FH and
FHL1.
Thus FH abnormalities have been reported in asso-
ciation with type II mesangiocapillary glomerulone-
phritis, SLE, recurrent meningococcal meningitis, and
HUS. Affected individuals in the two families with SLE
and meningococcal meningitis (Fijen et al. 1996; San-
chez-Corral et al. 2000) have had absent FH and, in one,
concurrent absence of FHL1, and the disorder has been
autosomal recessive. In the one case of mesangiocapil-
lary glomerulonephritis that has been studied exten-
sively, FH has been absent, but FHL1 levels were normal,
and, again, the disorder was autosomal recessive. For
HUS, both dominant and recessive pedigrees have been
reported. In some families, the FH level has been very
low, whereas in other cases it has been normal. From
the changes reported here, we hypothesize that muta-
tions in SCR 19/20 that affect the host recognition by
FH predispose to HUS. However, this does not explain
why the previously reported sporadic patient with half-
normal FH levels and one normal copy of the gene de-
veloped HUS, whereas adults with reduced FH levels in
the autosomal recessive pedigrees have not had a clinical
phenotype. Nor does it explain why, in the two reports
of low FH levels due to aberrant protein folding and
decreased secretion, the phenotype in one family is mes-
angiocapillary glomerulonephritis and in the other fam-
ily is HUS. However, hemizygous mutations in CCPs 19
and 20 do appear to be a cause of HUS. In the large
dominant pedigree with R1215Gwe reported elsewhere,
there was incomplete penetrance and, in the individual
in whom we have identified this change in this series, it
was inherited from an unaffected parent. Similarly, in
the other sporadic patient in this series for whom we
had parental samples, the change had been inherited
from an unaffected parent. Thus, in a proportion of
patients who present with typical sporadic HUS, there
will be an underlying genetic predisposition, and this
may have implications for other family members. It
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Figure 2 Amino acid sequence of the last two carboxy terminal CCPs for human, mouse, and sand bass FH and for human FHR1, 2,
3, and 4. The degree of homology at the mutation sites for patients 2, 3, 4, and 5 are shown by highlighting.
seems likely that the genetic change is a predisposing
factor and that an environmental insult then precipitates
the disorder, but it is possible that polymorphisms or
mutations in other genes modify the phenotype.
Finally, we have failed to identify mutations in 17
families and 28 individuals with HUS, despite use of a
method that is extremely sensitive in detection of single
base changes. Although this method does not detect large
deletions or genomic rearrangements, the low mutation-
detection rate in the familial cases suggests this may be
a heterogeneous condition. The family samples that we
have are not suitable for linkage studies, but microsat-
ellite markers in some of the families are not consistent
with a locus on chromosome 1q32 (unpublished data),
again suggesting involvement of additional genes.
In conclusion, mutations in FH exons 19/20 that affect
host recognition by FH predispose to HUS, but changes
in FH do not account for all cases of familial HUS. C3
and FH levels are not reliable as a screening test for FH-
associated HUS.
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